Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › ARQT

Pivotal bioVenture Partners Investment Advisor LLC position in ARQT

ARCUTIS BIOTHERAPEUTICS INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 1,008,174 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$26.6M, representing 10.86% of its reported portfolio and ranking #2 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed ARQT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.01M sh
Reported value held$26.65M
Portfolio Weight10.86%
First reportedQ3 2023
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's ARQT position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in ARQT in Q3 2023 at 1,105,309 shares (US$5.9M). The position peaked in Q3 2025 at 2,120,508 shares, worth US$40.0M. Across 13 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 1,008,174 shares valued at US$26.6M — a reduction of -257,109 shares quarter over quarter.. Notable position changes include a 73% increase in Q4 2023 (shares rose 207% over the following quarter), a 36% trim in Q4 2025 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.11M $5.87M New
Q4 2023 1.91M $6.17M Add
Q1 2024 2.03M $20.10M Add
Q2 2024 2.04M $18.98M Add
Q3 2024 2.12M $19.72M Add
Q4 2024 2.12M $29.54M Hold
Q1 2025 2.12M $33.16M Hold
Q2 2025 2.12M $29.73M Hold
Q3 2025 2.12M $39.97M Hold
Q4 2025 1.37M $39.69M Reduce
Q1 2026 1.36M $31.94M Reduce
Q2 2026 1.27M $33.18M Reduce
Q3 2026 1.01M $26.65M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARQT and 13F data

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARQT

All ARQT fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held ARQT?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed ARQT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in ARQT?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.01M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $26.65M, representing 10.86% of its reported portfolio and ranking #2.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling ARQT?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC reduced its position in ARQT. The position peaked in Q3 2025 at 2.12M shares.

Which other funds hold ARQT?

Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.